BR9508821A - Formulações líquidas de imunoglobulina - Google Patents

Formulações líquidas de imunoglobulina

Info

Publication number
BR9508821A
BR9508821A BR9508821A BR9508821A BR9508821A BR 9508821 A BR9508821 A BR 9508821A BR 9508821 A BR9508821 A BR 9508821A BR 9508821 A BR9508821 A BR 9508821A BR 9508821 A BR9508821 A BR 9508821A
Authority
BR
Brazil
Prior art keywords
immunoglobulin
immunoglobulin formulations
liquid immunoglobulin
preparations
amphiphilic stabilizers
Prior art date
Application number
BR9508821A
Other languages
English (en)
Inventor
Rene Bruegger
Katharina Gennari
Gerhard Hodler
Bernard Wuest
Original Assignee
Red Cross Found Cent Lab Blood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Cross Found Cent Lab Blood filed Critical Red Cross Found Cent Lab Blood
Publication of BR9508821A publication Critical patent/BR9508821A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9508821A 1994-09-08 1995-09-07 Formulações líquidas de imunoglobulina BR9508821A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418092A GB9418092D0 (en) 1994-09-08 1994-09-08 Organic compounds
PCT/EP1995/003522 WO1996007429A1 (en) 1994-09-08 1995-09-07 Liquid immunoglobulin formulations

Publications (1)

Publication Number Publication Date
BR9508821A true BR9508821A (pt) 1997-12-23

Family

ID=10761028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508821A BR9508821A (pt) 1994-09-08 1995-09-07 Formulações líquidas de imunoglobulina

Country Status (27)

Country Link
US (1) US5871736A (pt)
EP (1) EP0779818B1 (pt)
JP (1) JP3004729B2 (pt)
KR (1) KR100370631B1 (pt)
CN (1) CN1157572A (pt)
AT (1) ATE246005T1 (pt)
AU (1) AU700788B2 (pt)
BR (1) BR9508821A (pt)
CA (1) CA2197432C (pt)
CZ (1) CZ285967B6 (pt)
DE (1) DE69531400T2 (pt)
DK (1) DK0779818T3 (pt)
FI (1) FI970603A (pt)
GB (1) GB9418092D0 (pt)
HU (1) HU223668B1 (pt)
IL (1) IL115226A (pt)
MX (1) MX9701510A (pt)
NO (1) NO971016L (pt)
NZ (1) NZ292919A (pt)
PL (1) PL182738B1 (pt)
PT (1) PT779818E (pt)
RO (1) RO118568B1 (pt)
RU (1) RU2158605C2 (pt)
SK (1) SK282332B6 (pt)
TW (1) TW407056B (pt)
WO (1) WO1996007429A1 (pt)
ZA (1) ZA957583B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719265T2 (de) * 1996-09-06 2003-12-04 Chemo Sero Therapeut Res Inst Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP2116265B1 (en) * 2000-10-12 2020-12-23 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
CN102258464A (zh) 2003-04-04 2011-11-30 健泰科生物技术公司 高浓度抗体和蛋白制剂
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
AU2014201388C1 (en) * 2006-12-21 2017-02-02 Amgen Inc. Stable Buffered Formulations Containing Polypeptides
JP5513380B2 (ja) * 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合剤の組成物
ES2391798T3 (es) * 2007-07-10 2012-11-30 Medy-Tox, Inc. Composición líquida farmacéutica de toxina botulínica con estabilidad mejorada
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US8318161B2 (en) * 2009-03-06 2012-11-27 Genentech, Inc. Anti-oxidized LDL antibody formulation
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
JP5734985B2 (ja) 2009-09-17 2015-06-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
MX2012010198A (es) 2010-03-01 2012-10-03 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
EA027353B1 (ru) 2010-09-17 2017-07-31 Баксалта Инкорпорейтид СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
US20150157619A1 (en) * 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
SI3043776T1 (sl) 2013-09-11 2024-03-29 Eagle Biologics, Inc. Tekoče proteinske formulacije, ki vsebujejo vodotopna organska barvila
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
IL301681A (en) * 2020-09-27 2023-05-01 Emergent Biosolutions Canada Inc Hyperimmune globulin preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4360457A (en) * 1979-08-30 1982-11-23 Teijin Limited S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS60120823A (ja) * 1983-12-02 1985-06-28 Green Cross Corp:The ＩｇＧ単量体
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
HUT54308A (en) * 1989-04-04 1991-02-28 Lilly Co Eli Process for producing immunoglobulin conjugates and medicaments comprising same
JP2942412B2 (ja) * 1991-12-26 1999-08-30 鐘紡株式会社 化粧料

Also Published As

Publication number Publication date
SK30097A3 (en) 1997-10-08
AU3522995A (en) 1996-03-27
CZ68497A3 (en) 1997-06-11
DE69531400D1 (de) 2003-09-04
PL182738B1 (pl) 2002-02-28
CA2197432A1 (en) 1996-03-14
US5871736A (en) 1999-02-16
AU700788B2 (en) 1999-01-14
IL115226A (en) 1999-08-17
NO971016D0 (no) 1997-03-05
GB9418092D0 (en) 1994-10-26
MX9701510A (es) 1997-05-31
HUT77122A (hu) 1998-03-02
JP3004729B2 (ja) 2000-01-31
DE69531400T2 (de) 2004-05-27
NZ292919A (en) 1998-12-23
NO971016L (no) 1997-03-05
RO118568B1 (ro) 2003-07-30
CZ285967B6 (cs) 1999-12-15
IL115226A0 (en) 1995-12-31
WO1996007429A1 (en) 1996-03-14
EP0779818B1 (en) 2003-07-30
FI970603A0 (fi) 1997-02-12
CN1157572A (zh) 1997-08-20
PT779818E (pt) 2003-11-28
PL318265A1 (en) 1997-05-26
DK0779818T3 (da) 2003-11-24
TW407056B (en) 2000-10-01
FI970603A (fi) 1997-02-12
JPH10502938A (ja) 1998-03-17
SK282332B6 (sk) 2002-01-07
ATE246005T1 (de) 2003-08-15
HU223668B1 (hu) 2004-11-29
RU2158605C2 (ru) 2000-11-10
ZA957583B (en) 1997-03-10
KR100370631B1 (ko) 2003-04-18
CA2197432C (en) 2008-11-04
EP0779818A1 (en) 1997-06-25

Similar Documents

Publication Publication Date Title
BR9508821A (pt) Formulações líquidas de imunoglobulina
FI101303B (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamin o-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino£2,1-a|£2|bentsatsep iini- ja -oksatsino- ja -tiatsino£3,4-a|£2|bentsatsepiini-4-karboksyyl ihappojohdannaisten valmistamiseksi
NO924915D0 (no) Sakkarinderivater med inhiberende virkning paa protolytiske enzymer
ES2150664T3 (es) Nuevos derivados peptidos.
DK0691959T3 (da) Heterocykliske derivater som blodpladeaggregations-inhibitorer
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
NO941937D0 (no) Sakarinderivater som inhiberer proteolytiske enzymer
HUT65278A (en) Process for producing pyrido-, pyrrolo-, thiazino-, oxazino- and pyrazino-benzazepine derivatives and pharmaceutical preparations containing them
DE69709407T2 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
ATE130315T1 (de) Hirudin-derivate mit verzögerter wirkung.
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
OA09794A (fr) Dérivés de pyridone amino acide azetidinyl substitués, leur préparation et leur application en tant que médicaments.
DK573886D0 (da) Fremgangsmaade til fremstilling af beskyttede argininholdige peptider
FR2714291B1 (fr) Application des dérivés de la pyridone à titre de médicaments anesthésiques.
HUT65256A (en) Process for producing 2-mercapto methylene-tetrahydronaphtalene-2-carboxamide derivatives and pharmaceutical preparations containing them
DE3863499D1 (de) Schaedlingsbekaempfungsmittel auf basis von derivaten des 2,3-diaminomaleinsaeurenitrils.
HUP0000552A2 (hu) Egy O-(3-piperidino-2hidroxi-1-propil)-hidroximsav halogenidszármazék, annak alkalmazása, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
PC Transfer

Free format text: ZLB BIOPLASMA AG (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements